Video

The Oncologist-Patient Partnership

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man.
Delving into the Evaluation of JNJ-1900 Trial for Lung Cancer Treatment
Image of doctor.
Tagrisso Therapy Elicits Wave of New Therapeutic Approaches in NSCLC
Image of Dr. Boffa.
How Cancer Care Teams Can Help With the Cessation of Smoking
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Smoking Data May Guide Improved Lung Cancer Care and Patient Support
Image of Dr. Reznick
How to Best Navigate a Diagnosis of Lung and Head and Neck Cancer
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
The Benefit of Clinical Trial Enrollment for Patients With Cancer
Discussing the Mission of CURE With Our Former and New Editors-In-Chief
Discussing the Mission of CURE With Our Former and New Editors-In-Chief
a man and a woman in front of a dark blue background for CURE Speaking Out
How the FDA Approval of Imfinzi Advances Small Cell Lung Cancer Treatment
a man and a woman in front of a dark blue background for CURE Speaking Out
FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC
a man and a woman in front of a dark blue background for CURE Speaking Out
What the FDA Approval of Bizengri Means for Patients With NRG1-Positive NSCLC
Related Content
fda image.
May 29th 2025

Patritumab Deruxtecan BLA Withdrawn in Non-Small Cell Lung Cancer

Ryan Scott
The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in the U.S. has been withdrawn.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lungs.
May 28th 2025

Phase 1/2 Trial Investigating ATR-04 for EGFRi-Related Rashes in Lung Cancer

Ryan Scott
ATR-04 therapy is being investigated in the phase 1/2 ATR04-484 clinical trial for the treatment of EGFR inhibitor-associated rashes in lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
First-line Zepzelca plus Tecentriq led to survival improvements versus Tecentriq alone in patients with ES-SCLC: © stock.adobe.com.
May 22nd 2025

Zepzelca Plus Tecentriq Boosts Survival in First-Line ES-SCLC Care

Kristi Rosa
Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.
Image of lungs.
May 21st 2025

FDA Grants Fast Track Designation to ZL-1310 in Small Cell Lung Cancer

Spencer Feldman
ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage in most patients treated.